Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01057225 · FLOW

Participant flow

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma · Source last updated 2017-12-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 15 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 20 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG000
    title
    Phase I: Dose Level -1
  2. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 27 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG001
    title
    Phase I: Dose Level 0
  3. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 36 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG002
    title
    Phase I: Dose Level 1
  4. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 45 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG003
    title
    Phase I: Dose Level 2
  5. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 27 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG004
    title
    Phase II: Dose Level 0
  6. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 36 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG005
    title
    Phase II: Dose Level 1
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        6
      4. group Id
        FG003
        num Subjects
        7
      5. group Id
        FG004
        num Subjects
        22
      6. group Id
        FG005
        num Subjects
        23
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        6
      4. group Id
        FG003
        num Subjects
        7
      5. group Id
        FG004
        num Subjects
        22
      6. group Id
        FG005
        num Subjects
        23
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 15 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 20 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG000
    title
    Phase I: Dose Level -1
  2. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 27 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG001
    title
    Phase I: Dose Level 0
  3. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 36 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG002
    title
    Phase I: Dose Level 1
  4. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 45 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG003
    title
    Phase I: Dose Level 2
  5. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 27 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG004
    title
    Phase II: Dose Level 0
  6. description
    Patients receive: Oral 300 mg/m\^2 cyclophosphamide on days 1, 8, and 15; Oral 40 mg dexamethasone on days 1, 8, 15, and 22; Oral 100 mg thalidomide on days 1-28. Patients also recieve 20 mg/m\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 36 mg/m\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.
    id
    FG005
    title
    Phase II: Dose Level 1
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        6
      4. group Id
        FG003
        num Subjects
        7
      5. group Id
        FG004
        num Subjects
        22
      6. group Id
        FG005
        num Subjects
        23
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        6
      4. group Id
        FG003
        num Subjects
        7
      5. group Id
        FG004
        num Subjects
        22
      6. group Id
        FG005
        num Subjects
        23
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice